摄入omega-3脂肪酸会增强肥胖和控制不良的喘患者的支气管扩展反应
Katherine M Huether1, John Morgan Lamb1, Joan Skelly1
1University of Vermont, Burlington, VT, USA.
Respiratory medicine
|April 28, 2025
概括
欧米茄-3脂肪酸可以改善肥胖和控制不良的喘患者的支气管扩展器反应. 增加omega-3摄入量可以提高这种患者群体的药物有效性.
科学领域:
- 营养和呼吸系统健康
- 肥胖和喘管理管理
- 饮食中的脂肪酸和肺功能
背景情况:
- 肥胖与控制不良的喘和潜在降低支气管扩展剂的有效性有关.
- 饮食因素越来越多地被认为是它们在调节喘等慢性炎症疾病中的作用.
研究的目的:
- 研究饮食脂肪酸摄入量 (欧米茄-3和欧米茄-6) 与喘症状,控制和肥胖和控制不良喘的成年人肺功能之间的关系.
- 为了确定特定的脂肪酸是否会影响该群体的支气管扩展器反应.
主要方法:
- 一项涉及102名患有肥胖和控制不良喘的参与者的横截面研究.
- 使用亚利桑那州食物频率问卷评估的饮食摄入量.
- 使用标准化措施评估喘控制,症状,肺功能 (呼吸量计,支气管扩展剂反应).
主要成果:
- 在omega-3或omega-6摄入量与喘症状,控制或基线肺功能之间没有发现显著的关联.
- 支气管扩展剂的百分比反应与omega-3脂肪酸摄入量呈正相关性 (r=0.273,p=0.0074).
- 每增加1g的omega-3摄入量与百分比支气管扩展剂反应增加4%相关,在调整热量摄入量后.
结论:
- 饮食中的欧米茄-3脂肪酸可能对肥胖和控制不良的喘患者的支气管扩展剂反应产生积极影响.
- 改善饮食质量,特别是增加omega-3摄入量,可能会增强药物反应.
- 需要进一步的研究来证实这些发现,并探索其他饮食对药物反应的影响.
相关概念视频
01:26COPD: Management Using Bronchodilators and Corticosteroids
188
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
188
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
246
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
246
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
239
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
239
01:19Antiasthma Drugs: Leukotriene Modifiers
253
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
253
01:24Antiasthma Drugs: Methylxanthines
209
Theophylline, a member of the methylxanthine class of bronchodilators, has long been used in asthma management. While its exact mechanism of action is not fully understood, it is believed to have multiple effects on various cellular processes.
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
209
01:30Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K